

September 27, 2021

TEST REPORT

PN 160983

PHARMACEUTICAL SERVICES


Prepared For:

Dr. Chansamone Saiyasak
Nathan Trading Company Limited
58 Moo 12 Palan sub-District
Nathan District
Ubon Ratchathani 34170
Thailand

Prepared By:


Tiffany Heller
Manager, Pharmaceutical Services

Approved By:


Ana C Barbur, M.S.
Vice President, Analytical & Chemical Services

Rev 101218



An A2LA ISO 17025 Accredited Testing Laboratory — Certificate Numbers 255.01 & 255.02
ISO 9001:2015 Registered

ISO 9001:2015
Registered

Letters and reports are for the exclusive use of the clients to whom they are addressed and shall not be reproduced, except in full, without the written permission of Akron Rubber Development Laboratory, Inc. (ARDL). The information contained herein applies to the specific material, products or processes tested or evaluated. No warranty of any kind is herein construed or implied. The liability of ARDL, Inc. shall be limited to the amount of consideration paid for services. ARDL, Inc. is ISO 17025 accredited by A2LA for the test methods listed on the referenced certificates.

September 27, 2021

Dr. Chansamone Saiyasak
Nathan Trading Company Limited

Page 2 of 6
PN 160983

SUBJECT: Permeation testing per ASTM D6978-05(2019) on sample submitted by the above company.

RECEIVED: One (1) glove type identified by customer as: Lydus Nitrile Examination Gloves Powder Free, Non-Sterile, Size Medium, Color: Blue, Lot Number MG202006261.

TEST CHEMICALS:

Table 1. List of the Testing Drugs and their Sources

TESTING CHEMOTHERAPY DRUGS	DRUG SOURCE
Carmustine, 3.3 mg/ml (3,300 ppm)	USP; Lot# R116Y0; Expiration 08/2022
Cisplatin, 1 mg/ml (1,000 ppm)	Accord; Lot# P2001296; Expiration 01/2022
Cyclophosphamide, 20 mg/ml (20,000 ppm)	Accord; Lot# 19112225; Expiration 10/2021
Doxorubicin HCl, 2 mg/ml (2,000 ppm)	USP; Lot# R11760; Expiration 07/2022
Etoposide, 20 mg/ml (20,000 ppm)	Teva; Lot# 31328501B; Expiration 03/2023
Fluorouracil, 50 mg/ml (50,000 ppm)	Accord; Lot# P2001167; Expiration 01/2022
Methotrexate, 25 mg/ml (25,000 ppm)	Accord; Lot# P2004718; Expiration 05/2022
Paclitaxel, 6 mg/ml (6,000 ppm)	Teva; Lot# 19K24KA; Expiration 11/2021
Thiotepa, 10 mg/ml (10,000 ppm)	USP; Lot# R11380; Expiration 03/2022

COLLECTION MEDIA:

Table 2. Collection Media for Test Drug

TEST DRUG AND CONCENTRATION	COLLECTION MEDIUM
Carmustine, 3.3 mg/ml (3,300 ppm)	10% Ethanol Aqueous Solution
Cisplatin, 1 mg/ml (1,000 ppm)	Distilled Water
Cyclophosphamide, 20 mg/ml (20,000 ppm)	Distilled Water
Doxorubicin HCl, 2 mg/ml (2,000 ppm)	Distilled Water
Etoposide, 20 mg/ml (20,000 ppm)	Distilled Water
Fluorouracil, 50 mg/ml (50,000 ppm)	9.20 pH Sodium Hydroxide Solution
Methotrexate, 25 mg/ml (25,000 ppm)	Distilled Water
Paclitaxel, 6 mg/ml (6,000 ppm)	30% Methanol Aqueous Solution
Thiotepa, 10 mg/ml (10,000 ppm)	Distilled Water

TESTING CONDITIONS:

Standard Test Method Used: ASTM D6978-05(2019)
 Analytical Method: UV/VIS Spectrometry
 Testing Temperature: 35.0°C ± 2.0
 Collection System: Closed Loop
 Specimen Area Exposed: 5.067 cm²
 Selected Data Points: 25/test
 Number of Specimens Tested: 3/test
 Location Sampled From: Cuff Area

*ARDL is ISO 17025 accredited by A2LA for the test methods listed on the certificates referenced on page one. Unless specified, the current specification version is used.
 NOTE: Non-ISO 17025 accredited test methods are designated with the ^ symbol to differentiate from ISO 17025 accredited methods in the body of the test report.*

www.ardl.com | 2887 Gilchrist Rd. | Akron, Ohio 44305 | answers@ardl.com | Toll Free (800) 830-ARDL
 Fax (330) 794-6610 | Worldwide (330) 794-6600

September 27, 2021

Dr. Chansamone Saiyasak
Nathan Trading Company Limited

Page 3 of 6
PN 160983

DETECTION METHOD OF CHEMICAL PERMEATION:

UV/VIS ABSORPTION SPECTROMETRY:

Instrument: Perkin Elmer UV/VIS Spectrometer Lambda 25

UV/VIS Absorption Spectrometry was used to measure the absorbance of test chemicals, which permeated through the specimens into the collection medium. The collection medium was circulated in a closed loop through the testing period. Data collection was performed according to the programmed schedule by means of UV Winlab software from the Perkin Elmer Corporation. The list of the characteristic wavelengths is shown below.

Table 3. Characteristic Wavelengths used in UV/VIS Absorption Spectrometry

TESTING DRUG	WAVELENGTH (nm)
Carmustine, 3.3 mg/ml (3,300 ppm)	229
Cisplatin, 1 mg/ml (1,000 ppm)	199
Cyclophosphamide, 20 mg/ml (20,000 ppm)	200
Doxorubicin HCl, 2 mg/ml (2,000 ppm)	232
Etoposide, 20 mg/ml (20,000 ppm)	205
Fluorouracil, 50 mg/ml (50,000 ppm)	269
Methotrexate, 25 mg/ml (25)	303
Paclitaxel, 6 mg/ml (6,000 ppm)	231
Thiotepa, 10 mg/ml (10,000 ppm)	199

SAMPLE CHARACTERISTICS:

Table 4. Thickness characteristics for the tested: Lydus Nitrile Examination Gloves Powder Free, Non-Sterile, Size Medium, Color: Blue, Lot Number MG202006261.

Testing Drug (Customer Sample ID #)	Thickness (mm)			Average (mm)
	Sample 1	Sample 2	Sample 3	
Carmustine	0.075	0.078	0.080	0.078
Cisplatin	0.081	0.080	0.079	0.080
Cyclophosphamide	0.080	0.079	0.076	0.078
Doxorubicin HCl	0.080	0.080	0.078	0.079
Etoposide	0.082	0.083	0.077	0.081
Fluorouracil	0.077	0.080	0.083	0.080
Methotrexate	0.081	0.078	0.080	0.079
Paclitaxel	0.080	0.079	0.079	0.079
Thiotepa	0.080	0.077	0.080	0.079
Weight/Unit Area (g/m2)	81.4			

*ARDL is ISO 17025 accredited by A2LA for the test methods listed on the certificates referenced on page one. Unless specified, the current specification version is used.

NOTE: Non-ISO 17025 accredited test methods are designated with the ^ symbol to differentiate from ISO 17025 accredited methods in the body of the test report.*

September 27, 2021

Dr. Chansamone Saiyasak
Nathan Trading Company Limited

Page 4 of 6
PN 160983

RESULTS:

Table 5. Permeation Test Results on testing of: Lydus Nitrile Examination Gloves Powder Free, Non-Sterile, Size Medium, Color: Blue, Lot Number MG202006261.

TEST CHEMOTHERAPY DRUGS	MINIMUM BREAKTHROUGH DETECTION TIME (Specimen1/2/3) (Minutes)	AVERAGE STEADY STATE PERM. RATE (Specimen1/2/3) ($\mu\text{g}/\text{cm}^2/\text{minute}$)	OTHER OBSERVATIONS
Carmustine, 3.3 mg/ml (3,300 ppm)	38.7 (48.1,46.9,38.7)	0.7 (0.7,0.6,0.7)	Slight swelling and no degradation
Cisplatin, 1 mg/ml (1,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Cyclophosphamide, 20 mg/ml (20,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Doxorubicin HCl, 2 mg/ml (2,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Etoposide, 20 mg/ml (20,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Fluorouracil, 50 mg/ml (50,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Methotrexate, 25 mg/ml (25,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Paclitaxel, 6 mg/ml (6,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Thiotepa, 10 mg/ml (10,000 ppm)	27.7 (38.0,29.2,27.7)	0.2 (0.2,0.2,0.2)	Slight swelling and no degradation

*ARDL is ISO 17025 accredited by A2LA for the test methods listed on the certificates referenced on page one. Unless specified, the current specification version is used.
NOTE: Non-ISO 17025 accredited test methods are designated with the ^ symbol to differentiate from ISO 17025 accredited methods in the body of the test report.*

September 27, 2021

Dr. Chansamone Saiyasak
Nathan Trading Company Limited

Page 5 of 6
PN 160983

SAMPLES RECEIVED:

Lydus Nitrile Examination Gloves Powder Free, Non-Sterile, Size Medium, Color: Blue,
Lot Number MG202006261



*ARDL is ISO 17025 accredited by A2LA for the test methods listed on the certificates referenced on page one. Unless specified, the current specification version is used.
NOTE: Non-ISO 17025 accredited test methods are designated with the ^ symbol to differentiate from ISO 17025 accredited methods in the body of the test report.*

September 27, 2021

Dr. Chansamone Saiyasak
Nathan Trading Company Limited

Page 6 of 6
PN 160983

Appendix

Decision Rules

Rule 1. This is the way test results have traditionally been reported by ARDL. If ARDL runs a test for you that has pass/fail requirements, ARDL will report the values observed and then state "Pass" or "Fail" based on those values only. By default, ARDL will apply this rule to all Category I tests and those tests which are not on ARDL's Scope of Accreditation.

Rule 2. This rule takes into account the calculated measurement uncertainty of test results generated. Every test and piece of test equipment has an inherent amount of measurement uncertainty associated with it. Rule 2 establishes "Guard Bands", where the measurement uncertainty value is added to the Minimum Passing requirement and is subtracted from the Maximum Passing requirement. The Pass/Fail requirements thus become tighter and customers may be more "Certain" of their Pass/Fail result.

Rule 3. This rule also takes into account measurement uncertainty but does not set up guard bands. Rule 3 may be used when values are reported, but there is no Pass/Fail requirement called out in the test specification. Rule 3 simply states that the measurement uncertainty is reported to the customer, along with the testing result generated, and the customer decides if the results are suitable for their purposes.

REPORT REVISIONS:

<u>DATE</u>	<u>REVISION #</u>	<u>DETAILS</u>
09/27/2021	N/A	Original Final Report

Prepared By:


Tiffany Heller
Manager, Pharmaceutical Services

Approved By:


Ana C Barbur, M.S.
Vice President, Analytical & Chemical Services

*ARDL is ISO 17025 accredited by A2LA for the test methods listed on the certificates referenced on page one. Unless specified, the current specification version is used.
NOTE: Non-ISO 17025 accredited test methods are designated with the ^ symbol to differentiate from ISO 17025 accredited methods in the body of the test report.*